On November 30, 2017, the Company’s shareholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants and directors. The 2017 Plan allows for issuance of up to 2.2 shares of common stock. In addition, as of June 30, 2020, the Company may grant additional shares of common stock under the 2017 Plan with up to 0.1 options outstanding under its 2003 Plan and 4.5 options and restricted stock units outstanding under its 2010 Plan, that expire or are cancelled without delivery of shares of common stock.

The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. In September 2014, the Company began issuing restricted stock units (“RSUs”) in lieu of stock options. RSUs granted to employees generally vest ratably over four years on the anniversary date of the last day of the month in which the RSUs are granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional performance metrics are not met. Options and RSUs granted to the Company’s non-employee directors vest in full upon completion of one year of service on the Board following the date of the grant.

A summary of option activity is as follows for the fiscal year ended June 30, 2020:

				Weighted
	Number			average
	of			exercise
	shares			price
Options outstanding at beginning of year		5.5		$	24.45
Options granted		—		$	—
Less:
Options exercised		(0.4	)	$	22.56
Options canceled or expired		(0.3	)	$	26.69
Options outstanding at end of year		4.8		$	24.47
Options exercisable at end of year		4.8		$	24.47
Options vested and expected to vest		4.8		$	24.47

There were no options granted during the years ended June 30, 2020, 2019 and 2018.

The following table summarizes information about stock options outstanding at June 30, 2020:

	Options outstanding and exercisable
	Number		Weighted
	outstanding		average		Weighted
Range of	at		remaining		average
exercise	June 30,		contractual		exercise
prices	2020		life (years)		price
14.88 - 21.29		1.3		1.04	$	19.09
21.66 - 25.39		0.5		1.33		24.04
26.49 - 26.49		1.5		1.22		26.49
27.07 - 36.55		1.5		2.20		27.18
		4.8		1.49	$	24.47

As of June 30, 2020 there was no unrecognized share-based compensation expense related to stock options.

	2020
				Weighted
	Number			average
	of			grant date
	shares			fair value
RSUs outstanding at the beginning of year		2.4		$	37.70
RSUs granted		1.3			27.96
Less:
RSUs released		(0.9	)		35.63
RSUs canceled		(0.5	)		37.80
RSUs outstanding at end of year		2.3		$	32.50

The weighted average grant-date fair value of restricted stock units grants during the years ended June 30, 2020, 2019 and 2018 was $27.96, $46.62 and $32.67, respectively.

The fair value of restricted stock units that vested during the years ended June 30, 2020, 2019 and 2018 was $32.4, $27.6 and $20.4, respectively.

As of June 30, 2020, there was $38.2 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.1 years. We expect all unvested awards to vest and recognize forfeitures as they occur.

Share-based compensation expense recognized and included in the Consolidated Statements of Operations for the fiscal years ended June 30, 2020, 2019 and 2018 were as follows:

	Years Ended June 30,
	2020		2019		2018
Cost of molecular diagnostic testing	$	1.2	$	0.8	$	0.7
Cost of pharmaceutical and clinical services		0.3		0.2		0.2
Research and development expense		5.0		5.4		4.3
Selling, general, and administrative expense		18.7		27.1		21.9
Total share-based compensation expense	$	25.2	$	33.5	$	27.1

The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:

	As of
	June 30, 2020
Unrecognized share-based compensation cost	$	38.2
Aggregate intrinsic value of options outstanding	$	—
Aggregate intrinsic value of options fully vested	$	—
Aggregate intrinsic value of RSUs outstanding	$	25.9

The total intrinsic value of options exercised during 2020, 2019 and 2018 was as follows:

	Years Ended June 30,
	2020		2019		2018
Total intrinsic value of options exercised	$	8.8	$	0.4	$	17.0

On December 5, 2012, following shareholder approval, the Company adopted the 2012 Employee Stock Purchase Plan (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. At June 30, 2020, a total of 1.7 shares of common stock had been purchased under the 2012 Plan. Shares purchased under and compensation expense associated with the 2012 Plan for the years reported are as follows:

	Years Ended June 30,
	2020		2019		2018
Shares purchased under the plans		0.3		0.2		0.1
Plan compensation expense	$	1.7	$	1.0	$	0.1

From June 1, 2017 through May 31, 2018 there was an amendment to the 2012 Purchase Plan implemented such that the plan was non-compensatory. As of June 30, 2020, there is $0.7 unrecognized share-based compensation expense related to the 2012 Purchase Plan.

The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the following weighted-average assumptions:

	2020		2019		2018
Risk-free interest rate	1.8%		2.1%		2.1%
Expected dividend yield	0%			0%		0%
Expected life (in years)		0.5		0.5		0.5
Expected volatility	99%		55%		45%